PERIPHERAL T CELL LYMPHOMA
Clinical trials for PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control TerminatedThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Early trial of tazemetostat for tough T-Cell lymphoma halted after just 6 patients
Disease control TerminatedThis early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Lymphoma drug combo trial halted early
Disease control TerminatedThis study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in people with relapsed or hard-to-treat T and NK cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results ar…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows early promise for tough lymphoma
Disease control TerminatedThis early-phase trial tested a combination of two drugs, parsaclisib and chidamide, in 12 people with relapsed or refractory peripheral T-cell lymphoma. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated early, so results ar…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Lymphoma drug combo trial halted early – what we know
Disease control TerminatedThis early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were col…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC